Galectin Therapeutics
GALT
GALT
69 hedge funds and large institutions have $35.5M invested in Galectin Therapeutics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.79% more ownership
Funds ownership: 13.99% → 14.78% (+0.79%)
69% less call options, than puts
Call options by funds: $1.17M | Put options by funds: $3.83M
Holders
69
Holding in Top 10
–
Calls
$1.17M
Puts
$3.83M
Top Buyers
| 1 | +$2.49M | |
| 2 | +$1.94M | |
| 3 | +$657K | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$480K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$360K |
Top Sellers
| 1 | -$821K | |
| 2 | -$641K | |
| 3 | -$481K | |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$475K |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$398K |